2020
Quarter 1
|
2021
Quarter 1
|
Increase/
(decrease)
| ||||||||||
US$'000
|
US$'000
|
%
| ||||||||||
Point-of-Care
|
3,335
|
1,888
|
(43.4
|
)%
| ||||||||
Clinical Laboratory
|
17,842
|
23,706
|
32.9
|
%
| ||||||||
Total
|
21,177
|
25,594
|
20.9
|
%
|
$m
| |
Operating Profit
|
3.1
|
Depreciation
|
0.6
|
Amortisation
|
0.2
|
Share Option Expense
|
0.4
|
EBITDASO
|
4.3
|
(US$000's except share data)
|
Three Months
Ended
Mar 31,
2021
(unaudited)
|
Three Months
Ended
Mar 31,
2020
(unaudited)
| ||||||
Revenues
|
25,594
|
21,177
| ||||||
Cost of sales
|
(14,681
|
)
|
(11,901
|
)
| ||||
Gross profit
|
10,913
|
9,276
| ||||||
Gross profit %
|
42.6
|
%
|
43.8
|
%
| ||||
Other operating income
|
1
|
14
| ||||||
Research and development expenses
|
(1,437
|
)
|
(1,378
|
)
| ||||
Selling, general and administrative expenses
|
(6,019
|
)
|
(6,085
|
)
| ||||
Indirect share based payments
|
(380
|
)
|
(134
|
)
| ||||
Operating profit
|
3,078
|
1,693
| ||||||
Financial income
|
1
|
31
| ||||||
Financial expenses
|
(1,210
|
)
|
(1,232
|
)
| ||||
Net financing expense
|
(1,209
|
)
|
(1,201
|
)
| ||||
Profit before tax, once-off and non-cash items
|
1,869
|
492
| ||||||
Income tax expense
|
(105
|
)
|
(129
|
)
| ||||
Profit after tax before once-off and non-cash items
|
1,764
|
363
| ||||||
Non-cash financial expense
|
(162
|
)
|
(160
|
)
| ||||
Once-off items - closure costs
|
-
|
(2,425
|
)
| |||||
Profit/(loss) after tax
|
1,602
|
(2,222
|
)
| |||||
Earnings/(loss) per ADR (US cents)
|
7.7
|
(10.6
|
)
| |||||
Earnings per ADR (US cents)**
|
8.4
|
1.7
| ||||||
Diluted earnings/(loss) per ADR (US cents)
|
10.1
|
*
|
(4.2
|
)*
| ||||
Diluted earnings per ADR (US cents)**
|
10.1
|
*
|
5.3
|
*
| ||||
Weighted average no. of ADRs used in computing basic earnings per ADR
|
20,901,703
|
20,901,703
| ||||||
Weighted average no. of ADRs used in computing diluted earnings per ADR
|
27,222,372
|
25,467,516
|
Mar 31,
2021
US$ '000
(unaudited)
|
Dec 31,
2020
US$ '000
(unaudited)
| |||||||
ASSETS
| ||||||||
Non-current assets
| ||||||||
Property, plant and equipment
|
8,648
|
8,547
| ||||||
Goodwill and intangible assets
|
35,200
|
33,860
| ||||||
Deferred tax assets
|
4,205
|
4,185
| ||||||
Other assets
|
315
|
355
| ||||||
Total non-current assets
|
48,368
|
46,947
| ||||||
Current assets
| ||||||||
Inventories
|
37,582
|
30,219
| ||||||
Trade and other receivables
|
14,864
|
22,668
| ||||||
Income tax receivable
|
2,888
|
3,086
| ||||||
Cash and cash equivalents
|
32,277
|
27,327
| ||||||
Total current assets
|
87,611
|
83,300
| ||||||
TOTAL ASSETS
|
135,979
|
130,247
| ||||||
EQUITY AND LIABILITIES
| ||||||||
Equity attributable to the equity holders of the parent
| ||||||||
Share capital
|
1,213
|
1,213
| ||||||
Share premium
|
16,187
|
16,187
| ||||||
Treasury shares
|
(24,922
|
)
|
(24,922
|
)
| ||||
Accumulated surplus
|
12,561
|
10,573
| ||||||
Translation reserve
|
(5,189
|
)
|
(5,293
|
)
| ||||
Other reserves
|
23
|
23
| ||||||
Total deficit
|
(127
|
)
|
(2,219
|
)
| ||||
Current liabilities
| ||||||||
Income tax payable
|
389
|
154
| ||||||
Trade and other payables
|
30,881
|
26,488
| ||||||
Provisions
|
376
|
416
| ||||||
Total current liabilities
|
31,646
|
27,058
| ||||||
Non-current liabilities
| ||||||||
Exchangeable senior note payable
|
84,045
|
83,884
| ||||||
Other payables
|
15,625
|
16,619
| ||||||
Deferred tax liabilities
|
4,790
|
4,905
| ||||||
Total non-current liabilities
|
104,460
|
105,408
| ||||||
TOTAL LIABILITIES
|
136,106
|
132,466
| ||||||
TOTAL EQUITY AND LIABILITIES
|
135,979
|
130,247
|
(US$000's)
|
Three Months
Ended
Mar 31,
2021
(unaudited)
|
Three Months
Ended
Mar 31,
2020
(unaudited)
| ||||||
Cash and cash equivalents at beginning of period
|
27,327
|
16,400
| ||||||
Operating cash flows before changes in working capital
|
4,063
|
2,467
| ||||||
Changes in working capital
|
1,830
|
(1,396
|
)
| |||||
Cash generated from operations
|
5,893
|
1,071
| ||||||
Net interest and income taxes received
|
190
|
431
| ||||||
Capital expenditure and financing (net)
|
(2,196
|
)
|
(2,756
|
)
| ||||
Payments for leases (IFRS 16)
|
(701
|
)
|
(790
|
)
| ||||
Free cash flow
|
3,186
|
(2,044
|
)
| |||||
Payment of HIV/2 license fee
|
-
|
(1,112
|
)
| |||||
Proceeds received under Paycheck Protection Program
|
1,764
|
-
| ||||||
Cash and cash equivalents at end of period
|
32,277
|
13,244
|
Attachments
- Original document
- Permalink
Disclaimer
Trinity Biotech plc published this content on 27 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2021 10:16:13 UTC.